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1. Introduction 
A synovial sarcoma (SS) is a rare soft tissue sarcoma; in children and adolescents it accounts 
for 4 % of all non-rhabdomyosarcoma soft tissue sarcomas. The most common site of 
primary disease is the lower limbs. Although relatively rare, SS is the third most common 
extremity STS. In both children and adults three histopathologic subtypes of SS are 
described (monophasic, biphasic and poorly differentiated); it is associated with a 
characteristic translocation t(x;18) [23;17]. Despite considerable progress and achievements 
in child oncology, treating children with synovial sarcoma still remains a pressing problem. 
Numerous treatment options available today to children with SS and dispute among 
researchers show high importance of the issue and necessity of its complex study. 
2. Materials and methods 
Herein, we analyze the outcomes in 48 patients with various localizations of synovial 
sarcoma who were treated in N. N. Blokhin Cancer Research Centre between 1990 and 2007. 
The results were evaluated on 31 December 2010. The analyzed group was divided into two 
subgroups – the control group (historical control group) and the study group (experimental 
group) – matched for sex, age, localization of cancer, extent of tumor spread and recurrence. 
The mean age in the historical control group (1990-1999) was 10.41±4.03 years (range, 1.0 to 
15.0 years). The group included 29 pediatric patients – 13 males (44.8 %), 16 females (55.2%). 
20 (69.9%) test subjects were diagnosed with biphasic synovial sarcoma, 8 (27.6%) – with 
monophasic subtype and 1 (3.4%) – with poorly differentiated subtype. In all cases the 
diagnosis was based upon morphological study. Immunohistochemistry was used in 14 
(48.2%) cases to verify the diagnosis. The most likely localization of lesions was the lower 
extremity – 14 (48.3%) cases. 10 (34.5%) patients had lesions in upper extremities and 4 
(13.8%) in the trunk. One patient was diagnosed with retroperitoneal synovial sarcoma. 
Mean tumor volume in the control group was 49.1 cm3. 22 patients (75.9 %) had tumor size 
above 5 cm.  
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At the beginning of therapy 11 pediatric patients (37.9 %) had metastatic disease. Lung and 
lymph node (regional and distant) metastases were present in 8 (27.6%) and 2 (6.9%) 
patients respectively. One (3.4%) test subject had both lung and lymph node metastases. 15 
(51.7%) patients had recurrent disease. Control group therapy strategy included induction 
polychemotherapy (in the study we refer to induction PCT as chemotherapy courses given 
before local control which consisted of radiation therapy (RT) ± surgical treatment). 
Induction CT included IVA chemotherapy: Vincristine 1.5 mg/m2 o.d. IV push, 
Actinomycin 1500 mkg/m2 o.d. IV drip, Ifosfomide 3 g/m2 b.i.d. IV drip. Chemotherapeutic 
regimens used in the control group were rather inefficient – induction efficacy (Complete 
response + Partial response) was 28.6 %. 
Having analyzed the causes of low treatment efficacy in the control group, The Muscular – 
Skeletal Department and The Intensive Care, Reanimation and Bone Marrow 
Transplantation Department of N. N. Blokhin Cancer Research Centre developed an 
intensive CT protocol which included reinfusion of autologous haematopoetic stem cells 
derived from peripheral blood. The protocol was used in patients who developed soft tissue 
sarcomas with poor prognosis including synovial sarcoma. The article describes complex 
treatment of high-risk soft tissue sarcomas in pediatric patients with intensive consolidation 
CT (Cyclophosphamid – Etoposid – Carboplatin) and peripheral haematopoetic stem cell 
infusion. General therapy strategy included 4 induction CT courses, harvesting and 
cryoconservation of peripheral stem cells following hematopoetic stimulation by G-CSF, 
local control of primary tumor and consolidation CT. Local control consisted of surgical 
removal of primary tumor provided the technical resources were present and irradiation of 
primary tumor and metastases surviving induction CT. Consolidation CT included 4 
courses (additional to 4 main courses) analogous to induction CT. Intensive CT consisted of 
treatment with Etoposid 100  mg/m2 on day 1 – 5, Cyclophosphamid 400  mg/m2 on day 1 – 
5, Carboplatin 500  mg/m2 on day 4. 
Between 1999 and 2007 19 pediatric patients with synovial sarcoma were included in the 
treatment protocol: 9 (47.9 %) male, 10 female (52.6 %) with mean age 10.84±3.28 (range, 2.0 
to 15.0 years). Synovial sarcoma was diagnosed by light microscopy: 5 (26.3%) patients had 
a biphasic subtype, 12 (63.2 %) – a monophasic subtype and 2 (10.5%) – a poorly 
differentiated subtype. Verification of histological origin was performed with 
immunohistochemistry in 17 (89.4%) cases. In 13 (68.4 %) experimental group patients the 
diagnosis was verified through FISH (fluorescence in situ hybridization) with detection of a 
characteristic translocation t(X;18) and SYT - SSX (1 or 2) fusion genes. From 2004 till 2007 
year was performed 34 cytogenesis analysis by fluorescence in situ hybridization from 22 
biopsy for the histologic subtyping of soft tissue sarcomas, from 20 patients, none of whom 
had a previously established sarcoma diagnosis, and from 2 patients with recurrence of the 
disease.  Cytogenetic analysis confirmed the t(X;18)(p11;q11) in 13 cases, the 
t(11;22)(q24;q12) in 9 cases and t(2;13)(q35;q14) in 1 case, t(1;13)(p36;q14) in 2 cases. The 
samples were presented in impression smear -10 cases, fine-needle aspiration biopsy 
specimens – in 12 cases. We successfully verified the diagnosis of synovial sarcoma in 13 
cases, included relapses in 2 cases, extraosseous localization of Ewing's sarcoma in 6 cases 
and alveolar rhabdomyosarcoma in 3 cases. FISH allowed for establishing the diagnosis 
before obtaining microscopy results due to the study taking only 1 – 2 days and requiring an 
impression smear made right after biopsy.  
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The experimental group included 14 (73.7%) patients with primary tumor and 5 (26.3%) 
patients with recurrent disease. Primary tumor was classified according to the TNM staging 
system. In the study the patients were staged as follows: 7 (36.8%) patients had T2bN0M0, 2 
(10.5%) – T2bN1M0, 3 (15.8%) – T2bN0M1, 1 (5.3%) – TxN1M1 and 1 (5.3%) – TxN1M0. The 
most likely localization of lesions was the lower extremity – 10 (52.6%) cases. 3 (15.8%) 
patients had lesions in upper extremities and 5 (26.3%) in the trunk. One patient was 
diagnosed with synovial sarcoma of the lesser pelvis. Mean tumor volume in the 
experimental group was 59.8 cm3; 13 patients (68.4 %) had tumor size above 5 cm3 (12 – 
primary, 1 - recurring). In 2 (10.5%) patients with metastatic disease no primary tumor was 
found. Evident metastases were present at diagnosis in 8 (42.1%) experimental group 
patients. 1 (5.3%) patient had multiple metastases to the lungs, 1 (5.3%) – multiple 
metastases to bones and lungs, 1 (5.3%) – to regional lymph nodes and lungs, 1 (5.3%) – 
multiple metastases to lungs and soft tissues. Metastases to regional and distant lymph 
nodes were found in 4 (21.1%) cases. The above mentioned (tumor size, recurring and 
metastatic disease) made it possible to classify the experimental group as high-risk patients. 
Harvesting of peripheral stem cells was done after 2 induction CT courses provided bone 
marrow was intact on light microscopy. Leucopheresis was performed by continuous flow 
cell separators Baxter CS-3000 plus or CobeSpectra. Separation results (quantity of CD34+-
cells) were evaluated by a Becton Dickenson flow cytometer (USA) with the use of anti-
HPCA-2 monoclonal antibodies to CD34 in a Radioimmunology Laboratory of N. N. 
Blokhin Cancer Research Centre. Harvested peripheral stem cells underwent liquid nitrogen 
freezing with dimetylsulphoxide as a cryopreservation agent and were stored in the N. N. 
Blokhin Cancer Research Centre marrow bank.  
A total of 76 courses of induction CT were given. The mean interval between the courses 
was 23.33±0.49 days (range, 18 to 27 days). Evaluation of the induction CT toxicity showed 
that severe leucopenia (IV) developed during 61.0% of CT courses. The decline in leukocyte 
count to the absolute leukocyte count (ALC) of less than 1000 cells/μL was observed on the 
9.23±0.45 day since the beginning of CT. The maximum and minimum decline was up to 100 
cells/μL and 1600 cells/μL respectively. The peak of the decline was observed on the 
11.72±0.38 day. The mean duration of leucopenia (ALC < 1000 cells/μL) was 7.32±0.42 days 
(range, 1 to 13 days).  The  rise of leukocyte count to ALC > 1000 cells/μL was seen on the 
16.47±0.43 day. 44.1% of CT courses were associated with severe thrombocytopenia (IV).  
The decline in thrombocyte count to the absolute thrombocyte count (ATC) of less than 
75000 cells/μL was observed on the 11.92±0.37 day since the beginning of CT. The minimum 
and maximum decline was up to 20500 cells/μL and 1000 cells/μL respectively. The peak of 
the decline was observed on the 15.07±0.41 day. The mean duration of thrombocytopenia 
(ATC < 75000 cells/μL) was 10.66±1.25 days (range, 4 to 46 days).  The rise of thrombocyte 
count to ATC > 75000 cells/μL was seen on the 21.72±0.56 day. 23.7% of the CT courses 
were associated with severe anemia (IV). 
The decline in hemoglobin to 79 g/L was observed on the 10.43±0.65 day since the 
beginning of CT. The peak of the decline was observed on the 14.14±0.61 day. The mean 
duration of anemia (Hb < 79 g/L) was 8.00±0.8 days (range, 1 to 20 days).  The  rise of 
hemoglobin above 79 g/L was seen on the 18.69±0.94 day. 
Local control included 18 surgeries: 14 (73.7%) radical excisions, 2 (10.5%) non-radical 
excisions (with tumor cells at resection margins), 2 (10.5%) amputations and exarticulations. 
In 1 (5.3%) case no surgical local treatment was performed due to impossibility of radical 
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surgery. Therapeutic pathomorphosis in the remaining tumor was observed in 13 cases: 1 st. 
– 4 (30.7%), 2 st. – 7 (53.8%), 4 st. – 2 (15.5%). 17 (89.5%) patients underwent irradiation of 
primary tumor with total dose ranging from 45.6 to 32.2 Gy (1 patient received RT without 
surgical treatment, 16 patients had the site of an excised tumor irradiated). 2 (10.5%) patients 
did not receive RT due to amputation and exarticulation. 4 (21.0%) patients with multiple 
metastases to the lungs received large-field regional RT (total dose 12 Gy). Consolidation CT 
included 4 additional PCT courses analogous to induction CT with autologous peripheral 
stem cell infusion. A total of 76 courses of consolidation CT with hematopoetic support via 
peripheral blood stem cells without G-CSF stimulation were given. Median interval between 
courses was 26.00±0.54 days (range, 21 to 27 days). In order to provide hematopoietic 
support on the 7th day each PCT course was followed by reinfusion of low doses (CD34+ = 
0.9-1.5±0,1х106/kg) of peripheral stem cells. Evaluation of the consolidation CT toxicity 
showed that severe leucopenia (IV) developed during 74.6% of CT courses. The decline in 
leukocyte count to the absolute leukocyte count (ALC) of less than 1000 cells/μL was 
observed on the 8.35±0.36 day since the beginning of CT. The maximum and minimum 
decline was up to 100 cells/μL and 1800 cells/μL respectively. The peak of the decline was 
observed on the 11.35±0.34 day. The mean duration of leucopenia (ALC < 1000 cells/μL) 
was 7.47±0.49 days (range, 1 to 21 days).  The rise of leukocyte count to ALC > 1000 cells/μL 
was seen on the 16.00±0.45 day. 53.7% of CT courses were associated with severe 
thrombocytopenia (IV).  The decline in thrombocyte count to the absolute thrombocyte 
count (ATC) of less than 75000 cells/μL was observed on the 9.64±0.5 day since the 
beginning of CT. The maximum and minimum decline was up to 142000 cells/μL and 4000 
cells/μL respectively. The peak of the decline occurred on the 13.26±0.4 day. The mean 
duration of thrombocytopenia (ATC < 75000 cells/μL) was 11.45±0.73 days (range, 5 to 23 
days).  The rise of thrombocyte count to ATC > 75000 cells/μL was seen on the 21.58±0.74 
day. 29.9% of the CT courses were associated  with severe anemia (IV). The decline in 
hemoglobin to 79 g/L was observed on the 8.39±0.56 day since the beginning of CT. The 
peak of the decline occurred  on the 12.79±0.62 day. The mean duration of anemia (Hb < 79 
g/L) was 8.70±0.71 days (range, 1 to 20 days).  The rise of hemoglobin above 79 g/L was 
seen on the 16.72±0.68 day. 
3. Results 
Induction efficacy (Complete response + Partial response) was high (80% according to WHO 
criteria). Long-term outcome analysis has shown that of 18 patients in the control group 8 
(44.4%) patients are currently alive and 10 (55.6%) died due to disease progression after 
cessation of treatment. Disease recurrence was observed in 1.88±3.0 months (range, 0 to 9 
months). Of 11 patients in the experimental group only 2 (18.2%) died; metastatic disease 
developed on the 79th and 25th month. Of 11 control group patients with metastatic 
dissemination only 1 (9.0%) is alive – a female with synovial sarcoma of the right hip and 
metastases to regional lymph nodes. It should be noted that despite inductive PCT 
inefficiency, she underwent conservative surgery, namely tumor, soft tissue and regional 
inguinofemoral lymph node excision; no cancerous cells were found at resection margins. 
The patient received RT (total dose 45 Gy) to the site of an excised tumor and has been alive 
for 158 months. Other 10 (91.0%) patients died of underlying disease; recurrence developed 
within 5.3±10.8 months (range, 0 – 34 months). Of 8 experimental group patients with 
metastases 4 (50.0%) died: 1 – with metastases to the lymph nodes, 1 – with multiple 
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metastases to the lungs, 2 – with metastases to multiple sites (lungs + lymph nodes, lungs + 
bones). Death occurred on the 14th, 15th, 24th and 9th month; 3 patients died of recurring 
disease and metastatic dissemination to the lungs, 1 patient died of metastatic disease 
progression in the lungs and local recurrence. 4 (50.0%) test subjects are currently alive. 1 
patient is inoperable, having had metastases to the lungs, soft tissues and retroperitoneal 
lymph nodes upon first presentation; underwent PCT and RT, is currently alive. 1 patient 
had right calf tumor, metastases to popliteal and inguinofemoral lymph nodes; underwent 
complex treatment, was stabilized after PCT, is currently alive for 109 months with 
recurring metastases to the lungs. 2 patients with primary lesions in inguinofemoral lymph 
nodes and soft tissues of the thigh and calf are alive for 116 and 47 months with no signs of 
disease. 
The experimental and control group were compared on the basis of therapy results. The 
study analyzes relapse-free and overall survival in patients with synovial sarcoma. Worthy 
of note was the statistically significant (more than twofold) increase in relapse-free survival 
upon use of intensive CT regimen (Etoposid, Cyclophosphamid, Carboplatin) and 
hematopoetic support with autologous haematopoetic stem cells instead of standard 
therapy regimens. Thus, 2-year relapse-free survival of patients was 31.0±8.5% in the control 
group (who received standard treatment) and 66.1±11.3% in the experimental group. The 
difference was statistically significant (p=0.0097). Overall survival was also significantly 
higher: 3-year overall survival was 31.0±8.5% in the control group (who received standard 
treatment) and 75.6±10.6% in the experimental group (p=0,003). 
 
Characteristic Control group Experimental group 
Number of patients 18 11 
Alive 8(44,4%) 9 (81,8%) 
Died 10 (55,6%) 2 (18,2%) 
2-year relapse-free survival 31,0±8.5% 66.1±11.3% 
2-year overall survival 31.0±8.5% 75.6±10.6% 
Patients with metastases 11 (61,1%) 8 (72,7%) 
Died patients with metastases 10 (91%) 4 (50,0%) 
Table 1. Patient Characteristics 
4. Discussion 
Synovial sarcoma is characterized by infrequent occurrence and demand of histologic 
verification [12]. The use of fine-needle aspiration of the tumor and molecular genetic study 
as standard diagnostic methods allows for prompt establishment of diagnosis and therapy 
start [14]. Multiple research groups have proven the prognostic value of primary tumor size 
[7;10;11;4;9]. The majority of patients (75.9% in the control group and 68.4% in the 
experimental group) had tumor size more than 5 cm (in the study the largest diameter was 
taken to represent tumor size); median tumor volume in the control and experimental group 
was 49.1 cm3 and 59.8 cm3 respectively. At the beginning of therapy metastases were present 
in 37.9% and 42.1% of cases which led to attributing poor prognosis to these patients. It 
should be noted that no primary tumor was visualized in 2 pediatric patients with 
metastatic disease which shows high tumor aggressiveness and proneness to metastatic 
dissemination even with small tumor size. The study has proven high efficacy (80%) of 
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induction PCT in the experimental group which enabled conservative surgery to be 
performed due to tumor size regression. Adequate tumor excision (radical resection or 
broad surgical resection with “clean” cancer cell-free margins) is the cornerstone of therapy 
[19;21]; it was achieved in 89.5% of experimental group patients what correlates with data 
provided by foreign researchers [20].  
The advisability of postoperative RT in patients with synovial sarcoma remains a highly 
controversial issue. According to data [19;21;5;20] provided by the multi-factor analysis, 
the best relapse-free survival was shown in patients who underwent postoperative RT, 
especially with large primary tumor. Taking account of our experience and that of our 
foreign colleagues, we provided adjuvant RT to 84.2% of the experimental group; only 
10.5% of the patients did not receive RT due to operative mutilation. Adjuvant PCT was 
essential in patients with poor prognosis [6]: age – 10 years, lesion localization – trunk and 
extremities, primary tumor size above 5 cm (T2b), recurrent disease and regional/distant 
metastases upon diagnosis. Having analyzed the experience of 2 decades, European 
oncology pediatrics physicians came to the conclusion that PCT in children with SS is an 
essential asset of treatment (contrary to adult patients who do not respond to PCT). Thus 
pediatric patients with SS were included in rhabdomyosarcoma treatment protocol and 
received adjuvant PCT regardless of the risk [15;8;19]. J.J. Lewis et. аl, 2000 [16] studied 
112 cases of adult and adolescent SS; they observed 11 cases of local recurrence following 
only surgical treatment and 34 cases of metastatic dissemination to distant sites. Despite 
adequate operative treatment, almost 40% of patients developed distant metastases within 
5 years after treatment cessation, which undoubtedly calls for the development of a new 
effective systemic treatment. With 33-year experience M.F. Okcu et al, 2001 [18] believe 
complex therapy to provide better outcome. In 50% of inoperable pediatric patients with 
cancer preoperative CT yielded good results which enabled broad surgical resection to be 
performed. In high-risk pediatric patients (with primary tumor size above 5 cm and tumor 
extending outside the organ (T2b)) with localized synovial sarcoma who received complex 
treatment, 5-year relapse-free survival is 44 – 68% [10;11;4]. Worthy of note is the fact that 
the main factor limiting therapy intensification is hematological toxicity which increases 
with higher doses of anti-cancer drugs. Subtransplantation doses of peripheral blood stem 
cells as substitution treatment during hematopoetic suppression should be considered 
effective hematopoetic support. D.S. Hawkins et al., 2002 [13] used a combination of 
multi-cycle high-dose chemotherapy and hematopoetic support with peripheral blood 
stem cells to show that this method could be used in patients with stage IV 
rhabdomyosarcoma, desmoplastic small round cell tumor and malignant schwannoma. I. 
S. Dolgopolov et al., 1999 [1;2] gathered data indicating the possibility of giving multiple 
intensive CT courses with hematopoetic support via peripheral blood stem cells. 
Mobilizing peripheral blood stem cells with colony-stimulating factors after 1 – 2 PCT 
courses following their reinfusion in subtransplantation doses after 3 subsequent courses 
of PCT may facilitate the decrease of neutropenic fever. This, in turn, allows physicians to 
shorten intervals between PCT courses which may improve outcomes in high-risk 
pediatric patients with soft tissue sarcomas [3]. 2-year overall and relapse-free survival in 
young high-risk patients with synovial sarcoma in the experimental group was 
75.6±10.6% and 66.1±11.3% which corresponds to international data on analogous patient 
groups [22;6;20]. 
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5. Conclusions 
Intensive induction CT (Cyclophosphamid – Etopsid – Carboplatin) in high-risk patients 
with soft tissue sarcomas proved rather efficient (Complete response + Partial response = 
80.0%) compared to standard treatment strategies (28.6%) as well as tolerable provided there 
was adequate additional therapy. 
Collection of peripheral stem cells can be carried out after 1 – 2 induction CT courses 
(Cyclophosphamid – Etopsid – Carboplatin) and G-CSF administration in all patients. 
Reinfusion of low doses of peripheral blood stem cells (CD34+ = 0.9-1.5±0.1х106/kg) during 
adjuvant CT decreases hematological toxicity which allows consolidation CT to be done 
earlier when induction CT is already possible. 
Intensive CT regimen (Cyclophosphamid – Etopsid – Carboplatin) with hematopoetic 
support via infusion of autologous haematopoetic stem cells derived from peripheral blood 
significantly improves 2-year relapse-free survival compared to standard therapy strategies 
from 31.0±8.5% (control group) to 66.1±11.3% (experimental group). 
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whether a soft tissue mass is benign or malignant is vital for appropriate management. This book is the result
of collaboration between several authors, experts in their fields; they succeeded in translating the complexity of
soft tissue tumors and the diversity in the diagnosis and management of these tumors.
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